This suggests that the increase in ApoC-III during the development of atherogenic dyslipidemia may exacerbate insulin resistance, thereby accelerating the development of type 2 DM and hepatic steatosis [10,11,12]. This evidence concerns the gene APOC3 and metabolic syndrome.